Literature DB >> 22278599

Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis.

Min Ji Shin1, Sang Heon Song, Ihm Soo Kwak, Soo Bong Lee, Dong Won Lee, Eun Young Seong, Il Young Kim, Harin Rhee, Naria Lee.   

Abstract

BACKGROUND: There has been no study to investigate whether cystatin C could predict cardiovascular events in incident dialysis patients. We aimed to delineate the role of serum cystatin C and cystatin C-based estimated glomerular filtration rate (eGFR(cysC)) for prediction of cardiovascular events.
METHODS: This study included 66 end-stage renal disease patients who survived for >3 months after the start of dialysis, and serum cystain C levels were measured at the point of dialysis initiation.
RESULTS: Serum cystatin C was correlated with blood urea nitrogen (r = 0.537, p < 0.001), serum creatinine (r = 0.480, p < 0.001) and smoking (r = 0.284, p = 0.021). Cystatin C was inversely correlated with age (r = -0.316, p = 0.01) and eGFR(Cr) by modification of diet in renal disease (r = -0.533, p < 0.001). Kaplan-Meier analysis for cardiovascular events revealed that patients in the group with lower cystatin C levels (<4.14 mg/L) had a better event-free survival rate than patients in the group with higher cystatin C levels (≥4.14 mg/L) (p = 0.039). In univariate analysis, cystatin C (hazard ratio (HR) 2.62, p = 0.011) and eGFR(cysC) (HR 0.64, p = 0.004) were significant factors for the prediction of cardiovascular events. After multivariate adjustment, serum cystatin C and eGFR(cysC) were independent determinants of cardiovascular events (HR 3.952, p = 0.001 and HR 0.640, p = 0.004, respectively).
CONCLUSION: Serum cystatin C might be an independent marker of cardiovascular events in incident dialysis patients. Furthermore, eGFR(cysC) based on measured serum cystatin C could have a new role in predicting cardiovascular events beyond the estimation of true GFR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278599     DOI: 10.1007/s10157-011-0583-1

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  49 in total

1.  Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients.

Authors:  L Risch; R Herklotz; A Blumberg; A R Huber
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

2.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 3.  Arterial stiffness and renal replacement therapy.

Authors:  Constantijn J A M Konings; Marc Hermans; Jeroen P Kooman; Jan M Meinders; Arnold P G Hoeks; Frank M van der Sande; Karel M L Leunissen
Journal:  Perit Dial Int       Date:  2004 Jul-Aug       Impact factor: 1.756

4.  Cystatin C is more than GFR, and this may be a good thing.

Authors:  Andrew D Rule; John C Lieske
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

5.  Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study.

Authors:  David Singh; Mary A Whooley; Joachim H Ix; Sadia Ali; Michael G Shlipak
Journal:  Nephrol Dial Transplant       Date:  2007-01-08       Impact factor: 5.992

6.  Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate.

Authors:  Wolfgang Koenig; Dorothee Twardella; Hermann Brenner; Dietrich Rothenbacher
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

7.  Clinical utility of serum cystatin C in predicting coronary artery disease.

Authors:  Mevlut Koc; Mustafa Kemal Batur; Osman Karaarslan; Gülcan Abali
Journal:  Cardiol J       Date:  2010       Impact factor: 2.737

Review 8.  Cystatin C: an improved estimator of glomerular filtration rate?

Authors:  Omar F Laterza; Christopher P Price; Mitchell G Scott
Journal:  Clin Chem       Date:  2002-05       Impact factor: 8.327

9.  Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis.

Authors:  Elisabeth C Samouilidou; Eirini Grapsa
Journal:  Ren Fail       Date:  2008       Impact factor: 2.606

10.  Cystatin C as a risk factor for outcomes in chronic kidney disease.

Authors:  Vandana Menon; Michael G Shlipak; Xuelei Wang; Josef Coresh; Tom Greene; Lesley Stevens; John W Kusek; Gerald J Beck; Allan J Collins; Andrew S Levey; Mark J Sarnak
Journal:  Ann Intern Med       Date:  2007-07-03       Impact factor: 25.391

View more
  11 in total

1.  The association between creatinine versus cystatin C-based eGFR and cardiovascular risk in children with chronic kidney disease using a modified PDAY risk score.

Authors:  Sheena Sharma; Michelle R Denburg; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2017-05-08       Impact factor: 3.714

2.  Cystatin C as a biomarker of chronic kidney disease: latest developments.

Authors:  Stefanie W Benoit; Eileen A Ciccia; Prasad Devarajan
Journal:  Expert Rev Mol Diagn       Date:  2020-05-25       Impact factor: 5.225

3.  Serum β-trace protein and risk of mortality in incident hemodialysis patients.

Authors:  Tariq Shafi; Rulan S Parekh; Bernard G Jaar; Laura C Plantinga; Pooja C Oberai; John H Eckfeldt; Andrew S Levey; Neil R Powe; Josef Coresh
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-28       Impact factor: 8.237

4.  Cystatin C in children on chronic hemodialysis.

Authors:  Olivera Marsenic; Andrea Wierenga; Donna R Wilson; Michael Anderson; Tripti Shrivastava; Garfield A Simon; Anne M Beck; Tiffany J Swanson; Kathleen Studnicka; Dorit Elberg; Kevin Couloures; Martin A Turman
Journal:  Pediatr Nephrol       Date:  2012-11-21       Impact factor: 3.714

Review 5.  Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico.

Authors:  Maria Eleni Roumelioti; Thomas Nolin; Mark L Unruh; Christos Argyropoulos
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

6.  The occurrence and potential predictive factors of major adverse cardiac and cerebral events in end-stage renal disease patients on continuous ambulatory peritoneal dialysis: A prospective cohort study.

Authors:  Chunmeng Yao; Liping Zhou; Qinghe Huang
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

7.  Influence of point mutations on the stability, dimerization, and oligomerization of human cystatin C and its L68Q variant.

Authors:  Aneta Szymańska; Elżbieta Jankowska; Marta Orlikowska; Izabela Behrendt; Paulina Czaplewska; Sylwia Rodziewicz-Motowidło
Journal:  Front Mol Neurosci       Date:  2012-07-27       Impact factor: 5.639

8.  Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy.

Authors:  Xin Li; Hang Zhu; Peng Li; Qian Xin; Jie Liu; Wei Zhang; You-Hong Xing; Hao Xue
Journal:  J Geriatr Cardiol       Date:  2013-09       Impact factor: 3.327

9.  Association between renal damage markers and carotid atherosclerosis in Afro-descendants with hypertension belonging to a minority ethnic group from Brazil.

Authors:  Dyego José de Araújo Brito; Elisangela Milhomem Dos Santos; Raimunda Sheyla Carneiro Dias; Isabela Leal Calado; Gyl Eanes Barros Silva; Joyce Santos Lages; Francisco das Chagas Monteiro Júnior; Alcione Miranda Dos Santos; Natalino Salgado Filho
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

10.  GFR Estimation After Cystatin C Reference Material Change.

Authors:  Stefanie W Benoit; Thelma Kathman; Jay Patel; Melinda Stegman; Cristina Cobb; Jonathan Hoehn; Prasad Devarajan; Edward J Nehus
Journal:  Kidney Int Rep       Date:  2020-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.